The role of the taxanes in the treatment of older patients with advanced stage non-small cell lung cancer

Oncologist

Volumn 14, Issue 4, 2009, Pages 412-424

  Ramalingam, Suresh S ^a,b   Khuri, Fadlo R ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Aged; Carcinoma; Docetaxel; Elderly; Non small cell lung; Paclitaxel; Taxoids

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COMORBIDITY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; FEBRILE NEUTROPENIA; GERIATRICS; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; PACLITAXEL; PALLIATIVE CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TAXOIDS; TREATMENT OUTCOME;

EID: 66249148995     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0190     Document Type: Review

References (70)

1. Ries LAG, Melbert D, Krapcho M et al., eds. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, 2007. Available at http://seer.cancer.gov/csr/1975-2004/results-merged/sect-15-lung-bronchus.pdf, accessed March 10, 2008.
2. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067. (Pubitemid 30035956)
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Owonikoko TK, Ragin CC, Belani CP et al. Lung cancer in elderly patients: An analysis of the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2007;25:5570-5577.
5. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383-1389. (Pubitemid 46606420)
6. Mitka M. Too few older patients in cancer trials: Experts say disparity affects research results and care. JAMA 2003;290:27-28. (Pubitemid 37432859)
7. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-183. (Pubitemid 27084049)
8. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003;1(suppl 2):18-24.
9. Benson AB 3rd, Pregler JP, Bean JA et al. Oncologists' reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study. J Clin Oncol 1991;9:2067-2075.
10. Brown JS, Eraut D, Trask C et al. Age and the treatment of lung cancer. Thorax 1996;51:564-568. (Pubitemid 26226507)
11. Ramsey SD, Howlader N, Etzioni RD et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from Surveillance, Epidemiology and End Results - Medicare. J Clin Oncol 2004;22:4971-4978. (Pubitemid 46638623)
12. Chatta GS, Price TH, Stratton JR et al. Aging and marrow neutrophil reserves. J Am Geriatr Soc 1994;42:77-81. (Pubitemid 24020566)
13. Yancik R, Wesley MN, Ries LA et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: A population-based study. Cancer 1998;82:2123-2134. (Pubitemid 28240818)
14. Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in the older cancer patient: Clinical and economic considerations. Cancer Control 2000;7:539-547.
15. Lichtman SM, Villani G. Chemotherapy in the elderly: Pharmacologic considerations. Cancer Control 2000;7:548-556.
16. Gridelli C, Aapro M, Ardizzoni A et al. Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel. J Clin Oncol 2005;23:3125-3137. (Pubitemid 46224136)
17. Saliba D, Elliott M, Rubenstein LZ et al. The Vulnerable Elders Survey: A tool for identifying vulnerable older people in the community. J Am Geriatr Soc 2001;49:1691-1699. (Pubitemid 34007998)
18. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
19. Gridelli C, Perrone F, Gallo C et al.; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
20. Stinchcombe TE, Buzkova P, Choksi J et al. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2006;52:305-311. (Pubitemid 43674544)
21. Lilenbaum R, Rubin M, Samuel J et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2:306-311. (Pubitemid 47181713)
22. Ohe Y, Niho S, Kakinuma R et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15:45-50. (Pubitemid 38139602)
23. Yoshimura N, Kudoh S, Kimura T et al. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer: Final results. J Clin Oncol 2007;25:18161.
24. Simon GR, Extermann M, Chiappori A et al. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 2008;112:2021-2029.
25. Hainsworth JD, Erland JB, Barton JH et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: Results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 2003;5:33-38. (Pubitemid 36974738)
26. Hesketh PJ, Chansky K, Lau DH et al. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: A phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 2006;1:537-544. (Pubitemid 47181401)
27. Leong SS, Toh CK, Lim WT et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007;2:230-236. (Pubitemid 47181328)
28. Karampeazis A, Vamvakas L, Agelidou A et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): A randomized phase II Hellenic Oncology Research Group trial. J Clin Oncol 2007;25(18 suppl):7615.
29. Syrigos KN, Karapanagiotou E, Charpidou A et al. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced nonsmall cell lung cancer: A phase II study. J Chemother 2007;19:438-443. (Pubitemid 47236524)
30. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663. (Pubitemid 46630541)
31. Hainsworth JD, Spigel DR, Farley C et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: A randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007;110:2027-2034. (Pubitemid 350036863)
32. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104:2766-2774.
33. Langer CJ, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003;22:Abstract 2571.
34. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024. (Pubitemid 46606280)
35. Douillard J, Laporte S, Fossella F et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2:939-946. (Pubitemid 47511598)
36. Laporte S, Buyse M, Baroux N et al. Meta-analysis comparing docetaxel and vinca-alkaloids in the first-line treatment of NSCLC. Comparison of results based on individual patient data, study report data, and published data. Presented at the European Cancer Conference 14 (ECCO 14), Barcelona, Spain, September 23-27, 2007.
37. Tibaldi C, Bernardini I, Chella A et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer 2006;7:401-405. (Pubitemid 44043550)
38. Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006;24:4405-4411. (Pubitemid 46630978)
39. Fidias P, Supko JG, Martins R et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7:3942-3949. (Pubitemid 34044612)
40. Nakamura Y, Sekine I, Furuse K et al. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age. Cancer Chemother Pharmacol 2000;46:114-118. (Pubitemid 30624843)
41. Giorgio CG, Pappalardo A, Russo A et al. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 2006;51:357-362.
42. Okamoto I, Moriyama E, Fujii S et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005;35:188-194. (Pubitemid 40796852)
43. Choi IS, Kim BS, Park SR et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer 2003;39:99-101. (Pubitemid 36020301)
44. Pujol JL, Milleron B, Molinier O et al. Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study. J Thorac Oncol 2006;1:328-334. (Pubitemid 47163986)
45. Inoue A, Usui K, Ishimoto O et al. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:83-87. (Pubitemid 43340203)
46. Chen YM, Perng RP, Tsai CM et al. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. J Thorac Oncol 2006;1:141-145. (Pubitemid 47164001)
47. Marsland TA, Garfield DH, Khan MM et al. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: Results of two phase II, multicenter trials. Lung Cancer 2005;47:111-120. (Pubitemid 39643248)
48. Jatoi A, Stella PJ, Hillman S et al. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥65 years of age): A phase II North Central Cancer Treatment Group study. Am J Clin Oncol 2003;26:441-447. (Pubitemid 37248259)
49. Ramalingam S, Barstis J, Perry MC et al. Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: Subanalysis of a randomized trial. J Thorac Oncol 2006;1:240-244. (Pubitemid 47181441)
50. Comella P, Putzu C, Massidda B et al. Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase II trial. Lung Cancer 2007;56:263-271.
51. Comella P, Frasci G, Carnicelli P et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004;91:489-497. (Pubitemid 39093568)
52. Ramalingam S, Perry MC, Larocca RV et al. Outcome of elderly (>70 years) non-small cell lung cancer (NSCLC) patients on a multicenter, phase III randomized trial comparing weekly vs. standard schedules of paclitaxel (P) plus carboplatin (C). J Clin Oncol 2005;23(16 suppl):7149.
53. Hensing TA, Peterman AH, Schell MJ et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98:779-788. (Pubitemid 36959275)
54. Lilenbaum RC, Herndon JE 2nd, List MA et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 2005;23:190-196. (Pubitemid 41702638)
55. Ansari RH, Gonin R, Socinski M et al. Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):7665.
56. Langer CJ, Manola J, Bernardo P et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181. (Pubitemid 34162751)
57. Usui K, Inoue A, Ishimoto O et al. A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;23(18 suppl):7248.
58. Belani CP, Ramalingam S, Perry MC et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008;26:468-473.
59. Lilenbaum R, Socinski MA, Altorki NK et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006;24:4825-4832. (Pubitemid 46630908)
60. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
61. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
62. Kumar A, Soares HP, Balducci L et al. Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007;25:1272-1276. (Pubitemid 46646519)
63. Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
64. Crivellari D, Bonetti M, Castiglione-Gertsch M et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-1422. (Pubitemid 30205386)
65. ten Tije AJ, Verweij J, Carducci MA et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-1077.
66. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-1992.
67. Borkowski JM, Duerr M, Donehower RC et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol 1994;33:493-496. (Pubitemid 24082344)
68. Christman K, Muss HB, Case LD et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA 1992;268:57-62.
69. Gelman RS, Taylor SG 4th. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1404-1413. (Pubitemid 15179542)
70. Giovanazzi-Bannon S, Rademaker A, Lai G et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: An Illinois Cancer Center study. J Clin Oncol 1994;12:2447-2452. (Pubitemid 24346719)